Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039149213> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2039149213 endingPage "S21" @default.
- W2039149213 startingPage "S21" @default.
- W2039149213 abstract "Cognitive sequelae of opioid treatments for chronic pain are an important clinical concern. To assess cognitive effects of oxymorphone extended release (ER; 15 and 30 mg) and oxycodone controlled release (CR; 30 and 60 mg) in healthy nondependent recreational opioid users, an exploratory, randomized, double-blind, placebo-controlled 5-way crossover study was conducted. Subjects received single oral intact doses of opioids and placebo with a ≥7-day washout period between treatments. Sedation and cognitive effects were assessed using the Addiction Research Center Inventory Pentobarbital-Chlorpromazine-Alcohol Group (PCAG) scale, Alertness/Drowsiness Visual Analog Scale (A/D-VAS), and Divided Attention (DA) test. 35/40 (87.5%) subjects completed the study. Oxymorphone ER showed significantly less sedation than equianalgesic doses of oxycodone CR (oxymorphone ER 15 mg vs 30 mg; 30 mg vs 60 mg, respectively) on PCAG (mean Emax [SD] 6.0 [2.46] vs 8.2 [3.33], P<0.001; 7.4 [2.85] vs 9.5 [3.08] P<0.001) and A/D-VAS (mean Emin [SD] 35.8 [15.94] vs 24.0 [15.32] P<0.001; 28.7 [15.13] vs 14.0 [14.17], P<0.001). DA mean hit latency (reaction time Emax, msec) was significantly shorter for oxymorphone ER vs oxycodone CR (569.9 [79.59] vs 590.6 [75.46], P=0.03; 574.5 [88.36] vs 605.4 [92.62], P<0.001). DA mean percentage over road (Emin) was significantly greater for oxymorphone ER vs oxycodone CR (70.3% [12.81] vs 64.3% [16.69], P=0.007; 69.0 [16.20] vs 58.9% [15.40], P<0.001), indicating less tracking impairment. Mean percentage target hits (Emin) were 79.4% (17.01) vs 72.3% (20.03), P=0.02; and 79.2% (17.48) vs 64.8% (24.52) P<0.001 for oxymorphone ER vs oxycodone CR, suggesting decreased accuracy/attention with oxycodone CR. These exploratory data suggest that oxymorphone ER produces less sedation and less psychomotor and cognitive impairment than an equianalgesic dose of oxycodone CR. (Supported by Endo Pharmaceuticals Inc.)" @default.
- W2039149213 created "2016-06-24" @default.
- W2039149213 creator A5002986623 @default.
- W2039149213 creator A5013791504 @default.
- W2039149213 creator A5064837977 @default.
- W2039149213 creator A5068883650 @default.
- W2039149213 creator A5072909619 @default.
- W2039149213 creator A5091258261 @default.
- W2039149213 date "2010-04-01" @default.
- W2039149213 modified "2023-09-26" @default.
- W2039149213 title "Oral intact extended-release oxymorphone is associated with less cognitive and psychomotor impairment than equianalgesic doses of oral intact controlled-release oxycodone in healthy nondependent recreational opioid users" @default.
- W2039149213 doi "https://doi.org/10.1016/j.jpain.2010.01.091" @default.
- W2039149213 hasPublicationYear "2010" @default.
- W2039149213 type Work @default.
- W2039149213 sameAs 2039149213 @default.
- W2039149213 citedByCount "0" @default.
- W2039149213 crossrefType "journal-article" @default.
- W2039149213 hasAuthorship W2039149213A5002986623 @default.
- W2039149213 hasAuthorship W2039149213A5013791504 @default.
- W2039149213 hasAuthorship W2039149213A5064837977 @default.
- W2039149213 hasAuthorship W2039149213A5068883650 @default.
- W2039149213 hasAuthorship W2039149213A5072909619 @default.
- W2039149213 hasAuthorship W2039149213A5091258261 @default.
- W2039149213 hasBestOaLocation W20391492131 @default.
- W2039149213 hasConcept C126322002 @default.
- W2039149213 hasConcept C142724271 @default.
- W2039149213 hasConcept C170493617 @default.
- W2039149213 hasConcept C204787440 @default.
- W2039149213 hasConcept C27081682 @default.
- W2039149213 hasConcept C2776029756 @default.
- W2039149213 hasConcept C2776316548 @default.
- W2039149213 hasConcept C2776814716 @default.
- W2039149213 hasConcept C2781063702 @default.
- W2039149213 hasConcept C42219234 @default.
- W2039149213 hasConcept C71924100 @default.
- W2039149213 hasConcept C87813604 @default.
- W2039149213 hasConceptScore W2039149213C126322002 @default.
- W2039149213 hasConceptScore W2039149213C142724271 @default.
- W2039149213 hasConceptScore W2039149213C170493617 @default.
- W2039149213 hasConceptScore W2039149213C204787440 @default.
- W2039149213 hasConceptScore W2039149213C27081682 @default.
- W2039149213 hasConceptScore W2039149213C2776029756 @default.
- W2039149213 hasConceptScore W2039149213C2776316548 @default.
- W2039149213 hasConceptScore W2039149213C2776814716 @default.
- W2039149213 hasConceptScore W2039149213C2781063702 @default.
- W2039149213 hasConceptScore W2039149213C42219234 @default.
- W2039149213 hasConceptScore W2039149213C71924100 @default.
- W2039149213 hasConceptScore W2039149213C87813604 @default.
- W2039149213 hasIssue "4" @default.
- W2039149213 hasLocation W20391492131 @default.
- W2039149213 hasOpenAccess W2039149213 @default.
- W2039149213 hasPrimaryLocation W20391492131 @default.
- W2039149213 hasRelatedWork W1998718779 @default.
- W2039149213 hasRelatedWork W1999054691 @default.
- W2039149213 hasRelatedWork W2010097201 @default.
- W2039149213 hasRelatedWork W2042846329 @default.
- W2039149213 hasRelatedWork W2058485180 @default.
- W2039149213 hasRelatedWork W2480082914 @default.
- W2039149213 hasRelatedWork W2941629973 @default.
- W2039149213 hasRelatedWork W2977187351 @default.
- W2039149213 hasRelatedWork W3019069752 @default.
- W2039149213 hasRelatedWork W3185240436 @default.
- W2039149213 hasVolume "11" @default.
- W2039149213 isParatext "false" @default.
- W2039149213 isRetracted "false" @default.
- W2039149213 magId "2039149213" @default.
- W2039149213 workType "article" @default.